New call for malaria elimination

- Despite clear strategies and initiatives malaria has remained a leading cause of illness and death in most of Africa
  - Effective medicines and preventive tools exist BUT they reach only a small proportion of the population at risk

- In 2007 (Seattle): Bill and Melinda Gates challenged the global community to renew its commitment to end death from malaria

- Clarion call was taken up by the RBM Partnership and a global malaria action plan (GMAP) was formulated with a vision to end malaria suffering and death

- BUT-elimination CAN NOT BE possible if life saving commodities do not reach the people at risk
Universal coverage with effective tools is prerequisite for malaria elimination

Figure 1: Three components of the global strategy

Global Malaria Action Plan, Aug 2008

MMV’s Mission and Vision

• Discover, develop and deliver safe, effective and affordable antimalarials to treat and protect people most at risk of malaria

• Provide the public health community with the most appropriate tools to achieve maximum public health impact

• Our model is partnerships (academia, Pharma companies, endemic countries etc.)

Our vision is a world in which innovative medicines will cure and protect the millions at risk of malaria and help to ultimately eradicate this terrible disease.
MMV’s Research and Development (R&D) portfolio

- Coartem-D, a pediatric formulation has recently been approved and launched.
- Application for regulatory approval for Euratesim and Pyramax is planned soon.

MMV’s Global Access Model: Ensuring uptake and responsible use to maximize health impact
The reality: Big access gap to life saving medicines

<table>
<thead>
<tr>
<th>Country</th>
<th>% &lt;5 receiving any antimalarial</th>
<th>% &lt;5 receiving an ACT</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Burundi</td>
<td>30</td>
<td>3</td>
<td>MICS 2006</td>
</tr>
<tr>
<td>Cameroon</td>
<td>58</td>
<td>2</td>
<td>MICS 2006</td>
</tr>
<tr>
<td>CAR</td>
<td>57</td>
<td>3</td>
<td>MICS 2006</td>
</tr>
<tr>
<td>Cote d’Ivoire</td>
<td>36</td>
<td>3</td>
<td>MICS 2006</td>
</tr>
<tr>
<td>Djibouti</td>
<td>10</td>
<td>&lt;1</td>
<td>MICS 2006</td>
</tr>
<tr>
<td>The Gambia</td>
<td>63</td>
<td>&lt;1</td>
<td>MICS 2006</td>
</tr>
<tr>
<td>Ghana</td>
<td>61</td>
<td>4</td>
<td>MICS 2006</td>
</tr>
<tr>
<td>Malawi</td>
<td>24</td>
<td>&lt;1</td>
<td>MICS 2006</td>
</tr>
<tr>
<td>ST and P</td>
<td>25</td>
<td>6</td>
<td>MICS 2006</td>
</tr>
<tr>
<td>Sierra Leone</td>
<td>52</td>
<td>1</td>
<td>MICS 2006</td>
</tr>
<tr>
<td>Somalia</td>
<td>8</td>
<td>1</td>
<td>MICS 2006</td>
</tr>
<tr>
<td>Tanzania</td>
<td>58</td>
<td>2</td>
<td>DHS04-05</td>
</tr>
<tr>
<td>Togo</td>
<td>48</td>
<td>1</td>
<td>MICS 2006</td>
</tr>
<tr>
<td>Uganda</td>
<td>62</td>
<td>1</td>
<td>DHS, 2006</td>
</tr>
<tr>
<td>Zambia</td>
<td>58</td>
<td>13</td>
<td>MICS 2006</td>
</tr>
</tbody>
</table>

Bridging the access gap through Home Management of Malaria (HMM)

- A care delivery strategy to increase access to effective treatment for malaria
  - Where the health care system is far or weak
  - Where self-treatment is common
  - Where self-treatment is often inappropriate
Key elements of HMM

- Effective, pre-packaged, user-friendly, unit-dosed, antimalarials (ACTs)

- Made available close to the home through a network of trained community-based providers...

- Backed up by a communication strategy for behaviour change

TDR research on HMM

Feasibility, acceptability studies ± effectiveness (6): GHA, NIG, UGA, BEN, SUD
Urban HMM (7): ETN, UGA, BFA, GHA, MWI, CAM
RDT studies (6): UGA, GHA, CAM, NIG, BFA, ZAM
ACT delivery through Private Sector (1): KEN
Community Case Management of fevers (3): UGA, GHA, BFA
Impact studies (3+1): BFA, DRC, MWI, CAM
Key Findings

- CMDs can deliver ACTs with high quality (>95%)
- Mothers adhere to treatment schedule (85%)
- Coverage of malaria (fever) cases by CMDs is high (~60%)
- Cure rate of ACTs in HMM is high (>90%)
- Coartem is stable when stored by CMDs
- HMM reduces workload in Health Facilities

Bridging the access gap in the private sector-Uganda's experience with subsidized medicines

- Aligning policy for wider distribution of ACTs- OTC status
- Training care providers
- Supply chain incentives to stock ACTs- Adequate margins
- Generating demand for umbrella brand (ACT-leaf)
- Tracking progress, safety and impact

Feasibility and acceptability of the use of artemether-lumefantrine in the home management of uncomplicated malaria in children 6–59 months old in Ghana

Malaria Journal

Feasibility and acceptability of artemisinin-based combination therapy for the home management of malaria in four African sites

Malaria Journal

Effectiveness of artemisinin-based combination therapy used in the context of home management of malaria: A report from three study sites in sub-Saharan Africa

Malaria Journal

Implementation of Home based management of malaria in children reduces the work load for peripheral health facilities in a rural district of Burkina Faso

Medicines for Malaria Venture
Subsidized medicines have eroded chloroquine (CQ) and other antimalarials market share for patients >5 years.

Furthermore, patients have paid an average price of $0.25 for treatment course, and $0.10 for children.
HMM needs effective integration into the Health System

- Efficient public sector supply chain
- HMM not an alternative but part of overall malaria case management policy
- Supportive supervision from Health Facilities

To be successful, HMM requires a performing Health System

Challenges in HMM implementation

- **Incentive scheme for CHWs - monetary / non monetary**
  - Key factor in performance of HMM under programme conditions
  - To reduce attrition of CHW
  - To reduce costs e.g. re-training
  - To improve performance

- **Effective supervision and feedback of CHWs**
  - Key factor in performance of HMM under programme conditions
  - To improve performance
  - To improve health outcomes
  - To reduce burden on Health System

- **Other issues**
  - Instructions to facilitate easy use and packaging
  - Child friendly formulations
Research gaps – evidence needed

- Safety and effectiveness of ACTs used at large scale in the HMM context
- Feasibility of incorporating RDTs and cost effectiveness in different transmission settings
- Impact on mortality and severe morbidity with ACT
- Is there a role of HMM in urban areas? (Staedke et al, 2009)
- Impact of the private sector in community based ACT distribution-AMFm
- Impact of AMFM on CMDs–ACT sales vy free in the same communities

Acknowledgements

- Access and Science team at MMV
- Dr. Franco Pagnoni- WHO, TDR
- CAPSS team (Uganda MoH, MMV, PACE/PSI,NDA SURGIPHARM, I+SOLUTIONS, MC, the Districts)